Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: A systematic review and meta-analysis

PLoS Medicine

Volumn 6, Issue 9, 2009, Pages

  Menzies, Dick ^a   Benedetti, Andrea ^a   Paydar, Anita ^a   Martin, Ian ^a   Royce, Sarah ^b   Pai, Madhukar ^a   Vernon, Andrew ^c   Lienhardt, Christian ^d   Burman, William ^e  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^e DENVER PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; HUMAN; LUNG TUBERCULOSIS; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REGRESSION ANALYSIS;

ANTIBIOTICS, ANTITUBERCULAR; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; HUMANS; ISONIAZID; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; REGRESSION ANALYSIS; RIFAMPIN; RISK FACTORS; STREPTOMYCIN; TREATMENT FAILURE; TUBERCULOSIS, PULMONARY;

EID: 70349634546     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1000146     Document Type: Review

References (117)

1. Fox W, Ellard GA, Mitchison DA (1999) Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 3: S231-S279. (Pubitemid 29481843)
2. World Health Organization (2004) Treatment of tuberculosis: guidelines for national programmes WHO/CDS/TB/2003.313 (Revised June 2004). WHO 313: 1-108.
3. Mitchison DA, Nunn AJ (1986) Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 133: 423-430. (Pubitemid 16126276)
4. Caminero JA (2006) Treatment of multidrug resistant tuberculosis: evidence and controversies. Int J Tuberc Lung Dis 10: 829-837. (Pubitemid 44197841)
5. Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, et al. (2001) Global trends in resistance to antituberculosis drugs. World Health Organization- International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 344: 1294-1303.
6. World Health Organization (2008) Anti-tuberculosis drug resistance in the world (Report no. 4). WHO/HTM/TB/2008.
7. WHO and IUATLD (2008) Anti-tuberculosis drug resistance in the world (Report no. 4).
8. Han T (2006) Effectiveness of standard short-course chemotherapy for treating tuberculosis and the impact of drug resistance on its outcome. Int J Evid Based Healthc 4: 101-117.
9. Mwandumba HC, Squire SB (2008) Fully intermittent dosing with drugs for treating tuberculosis in adults. Cochrane Database of Systematic Reviews.
10. Cox HS, Morrow M, Deutschmann PW (2008) Long term efficacy of DOTS regimens for tuberculosis: systematic review. BMJ 336: 484-487. (Pubitemid 351350598)
11. Gelband H (1999) Regimens of less than six months for treating tuberculosis (review). Cochrane Database of Systematic Reviews 1.
12. Fox W, Ellard GA, Mitchison DA (1999) Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 3: S231-S279. (Pubitemid 29481843)
13. American Thoracic Society, Infectious Diseases Society of America, Centres for Disease Control (2003) Treatment of tuberculosis. Am J Respir Crit Care Med 167: 603-662.
14. Public Health Agency of Canada and Canadian Lung Association/Canadian Thoracic Society (2007) Canadian tuberculosis standards. Toronto: Canadian Lung Association, Public Health Agency of Canada, Tuberculosis Prevention and Control.
15. Page KR, Chaisson RE (2006) Tuberculosis - HIV coinfection: epidemiology, clinical aspects, and interventions. In: Raviglione MC, ed. Reichman and Hershfield's tuberculosis a comprehensive, international approach. New York: Informa HealthCare. pp. 371-416.
16. Rieder HL (2002) Interventions for tuberculosis control and elimination. Paris: International Union against Tuberculosis and Lung Disease.
17. World Health Organization, International Union against Tuberculosis and Lung Disease (IUATLD), Royal Netherlands Tuberculosis Association (2001) Revised international definitions in tuberculosis control. Int J Tuber Lung Dis 5: 213-215.
18. Bradburn MJ, Deeks JJ, Berlin JA, Localio AR (2007) Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Statist Med 26: 53-77.
19. Higgin JPT, Thompson SG (2004) Controlling the risk of spurious findings from meta-regression. Stat Med 23: 1663-1682.
20. Hamza TH, Houwelingen HC, Stijnen T (2008) The binomial distribution of meta-analysis was preferred to model within-study variability. J Clin Epidemiol 61: 41-51.
21. Glasziou PP, Sanders SL (2002) Investigating causes of heterogeneity in systematic reviews. Stat Med 21: 1503-1511.
22. Thompson SG, Sharp SJ (1999) Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 18: 2693-2708.
23. Singapore Tuberculosis Service, British Medical Research Council (1975) Controlled trial of intermittent regimens of rifampicin plus isoniazid for pulmonary tuberculosis in Singapore. Lancet 306: 1105-1109.
24. East African-British Medical Research Council Study (1972) Controlled clinical trial of short-course (6 month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 299: 1079-1085.
25. Tuberculosis Research Centre (1983) Study of chemotherapy regimens of 5 and 7 months' duration and the role of corticosteroids in the treatment of sputum-positive patients with pulmonary tuberculosis in South India. Tuberc 64: 73-91.
26. Jindani A, Nunn AJ, Enarson DA (2004) Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 364: 1244-1251. (Pubitemid 39311345)
27. Singapore Tuberculosis Service-British Medical Research Council (1977) Controlled trial of intermittent regimens of rifampin plus isoniazid for pulmonary tuberculosis in Singapore. the results up to 30 months. Am Rev Respir Dis 116: 807-820.
28. Hong Kong Chest-British Medical Research Council (1981) Controlled trial of four twice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Lancet 317: 171-174.
29. Balasubramanian R, Sivasubramanian S, Vijayan VK, Ramachandran R, Jawahar MS, et al. (1990) Five year results of a 3-month and two 5-month regimens for the treatment of sputum-positive pulmonary tuberculosis in south India. Tuberc 71: 253-258.
30. East African-British Medical Research Council (1973) Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. second report. Lancet 1: 1331-1338.
31. East African-British Medical Research Council (1974) Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. third report. Lancet 2: 237-240.
32. East African-British Medical Research Council (1976) Controlled clinical trial of four (6-month) 3 regimens of chemotherapy for pulmonary tuberculosis. second report. Am Rev Respir Dis 114: 471-475.
33. Third East African-British Medical Research Council (1978) Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis: first report. Am Rev Respir Dis 118: 39-48.
34. Third East African-British Medical Research Council (1980) Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. second report. Tuberc 61: 59-69.
35. Hong Kong Chest Service and British Medical Research Council (1978) Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis. first report. Am Rev Respir Dis 118: 219-228.
36. Hong Kong Chest Service and British Medical Research Council (1979) Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis: the results up to 24 months. Tuberc 60: 201-210. (Pubitemid 10167304)
37. Singapore Tuberculosis Service-British Medical Research Council (1979) Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 119: 579-585.
38. Singapore Tuberculosis Service-British Medical Research Council (1981) Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis: the results up to 30 months. Tuberc 62: 95-102. (Pubitemid 11094277)
39. Singapore Tuberculosis Service-British Medical Research Council (1986) Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 133: 779-783. (Pubitemid 16116502)
40. Hong Kong Chest Service-British Medical Research Council (1982) Controlled trial of 4 three-times-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. second report: the results up to 24 months. Tuberc 63: 89-98. (Pubitemid 12073429)
41. Hong Kong Chest Service-British Medical Research Council (1987) Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 136: 1339-1342.
42. Algerian Working Group-British Medical Research Council (1984) Controlled clinical trial comparing a 6-month and a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Am Rev Respir Dis 129: 921-928.
43. East and Central African-British Medical Research Council (1983) Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis. Tuberc 64: 153-166.
44. East and Central African-British Medical Research Council Fifth Collaborative (1986) Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. Tuberc 67: 5-15. (Pubitemid 16160349)
45. Tanzania-British Medical Research Council (1985) Controlled clinical trial of two 6-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 131: 727-731. (Pubitemid 15066858)
46. Singapore Tuberculosis Service-British Medical Research Council (1985) Clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 132: 374-378.
47. Singapore Tuberculosis Service-British Medical Research Council (1988) Five-year follow-up of a clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 137: 1147-1150.
48. Hong Kong Chest Service-Tuberculosis Research Centre MBMRC (1991) A controlled clinical comparison of 6 and 8 months of antituberculosis chemotherapy in the treatment of patients with silicotuberculosis in Hong Kong. Am Rev Respir Dis 143: 262-267.
49. Hong Kong Chest Service-British Medical Research Council (1991) Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. results at 30 months. Am Rev Respir Dis 143: 700-706.
50. Singapore Tuberculosis Service-British Medical Research Council (1991) Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Am Rev Respir Dis 143: 707-712.
51. Kenyan-Zambian-British Medical Research Council (1989) Controlled clinical trial of levamisole in short-course chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 140: 990-995.
52. Tuberculosis Research Centre Madras (1986) A controlled clinical trial of 3- and 5-month regimens in the treatment of sputum-positive pulmonary tuberculosis in South India. Am Rev Respir Dis 134: 27-33. (Pubitemid 16057455)
53. British Medical Research Council (1973) Co-operative controlled trial of a standard regimen of streptomycin, PAS and isoniazid and three alternative regimens of chemotherapy in Britain. Tuberc 54: 99-129.
54. British Thoracic and Tuberculosis Association (1975) Short-course chemotherapy in pulmonary tuberculosis. Lancet 305: 119-124.
55. British Thoracic and Tuberculosis Association, Angel H (1976) Short-course chemotherapy in pulmonary tuberculosis. a controlled trial by the British Thoracic and Tuberculosis Association. Lancet 2: 1102-1104.
56. British Thoracic Association (1981) A controlled trial of six months chemotherapy in pulmonary tuberculosis. first report: results during chemotherapy. Br J Dis Chest 75: 141-153. (Pubitemid 11096845)
57. Zierski M, Bek E, Long MW, Snider DE, Jr. (1981) Short-course (6-month) cooperative tuberculosis study in Poland: results 30 months after completion of treatment. Am Rev Respir Dis 124: 249-251.
58. British Thoracic Association (1982) A controlled trial of six months chemotherapy in pulmonary tuberculosis. second report: results during the 24 months after the end of chemotherapy. Am Rev Respir Dis 126: 460-462.
59. Macnab MF, Bohmer PD, Seager JR (1994) Evaluation of the 3-drug combination, Rifater, versus 4-drug therapy in the ambulatory treatment of tuberculosis in Cape Town. S Afr Med J 84: 325-327.
60. Felten MK (1989) Importance of rifampicin in combined daily/intermittent chemotherapy for tuberculosis. S Afr Med J 75: 524-526.
61. Kohno S, Koga H, Kaku M, Maesaki S, Hara K (1992) Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis. Chest 102: 1815-1818. (Pubitemid 23001233)
62. Gonzalez-Montaner LJ, Natal S, Yongchaiyud P, Olliaro P, the Rifabutin Study Group (1994) Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus rifampicin. Tuberc Lung Dis 75: 341-347. (Pubitemid 24336530)
63. Algerian Working Group British Medical Research Council Cooperative Study (1991) Short-course chemotherapy for pulmonary tuberculosis under routine programme conditions: a comparison of regimens of 28 and 36 weeks duration in Algeria. Tuberc 72: 88-100.
64. Tripathy SP (1983) Controlled clinical trial of a 3-month and two 5-month regimens in pulmonary tuberculosis. Second Madras short course study. Bull Int Union Tuberc 58: 97-100.
65. Su W-J, Perng R-P (2002) Fixed-dose combination chemotherapy (Rifater/ Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up. Int J Tuberc Lung Dis 6: 1029-1032.
66. Zhang LX, Kan GQ, Tu DH, Wan LY, Faruqi AR (1996) Fixed-dose combination chemotherapy versus multiple, single-drug chemotherapy for tuberculosis. Curr Ther Res 57: 849-856.
67. Corpe R (1972) Rifampin in original treatment of pulmonary tuberculosis: a United States public health service cooperative therapy trial. Bull Int Union Tuberc 47: 41-47.
68. Howell F, O'Laoide R, Kelly P, Power J, Clancy L (1989) Short course chemotherapy for pulmonary tuberculosis: a randomised controlled trial of a six month versus a nine month oral regimen. Ir Med J 82: 11-13. (Pubitemid 19069393)
69. Snider DE, Gracyk J, Bek E, Rogowski J (1984) Supervised six-months treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampin, and pyrazinamide with and without streptomycin. Am Rev Respir Dis 130: 1091-1094. (Pubitemid 15186171)
70. Santha T, Nazareth O, Krishnamurthy MS, Balasubramanian R, Vijayan VK, et al. (1989) Treatment of pulmonary tuberculosis with short course chemotherapy in south India-5 year follow up. Tuberc 70: 229-234. (Pubitemid 20001742)
71. Shenna DH (1984) Comparison of a conventional and an initial 2-month intensive drug regimen for treating pulmonary tuberculosis in Swaziland. Tuberc 65: 101-104.
72. Perriens JH, St. Louis M, Mukadi YB, Brown C, Prignot J, et al. (1995) Pulmonary tuberculosis in HIV-infected patients in Zaire. N Engl J Med 332: 779-784.
73. Tam CM, Chan SL, Lam CW, Leung CC, Kam KM, et al. (1998) Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Am J Respir Crit Care Med 157: 1726-1733. (Pubitemid 28311251)
74. Combs D, O'Brien R, Geiter LJ (1990) USPHS tuberculosis short-course chemotherapy trial 21: effectiveness, toxicity, and acceptability. Ann Intern Med 112: 397-406.
75. Pedral-Sampaio DB, Netto EM, Brites C, Bandeira AC, Guerra C, et al. (2003) Use of Rhu-GM-CFS in pulmonary tuberculosis patients: results of a randomized clinical trial. Braz J Infect Dis 7: 245-252.
76. Hong Kong Chest Service, Tuberculosis Research Centre M, British Medical Research Council (1984) A controlled trial of 2-month, 3-month, and 12-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Am Rev Respir Dis 130: 23-28. (Pubitemid 14092974)
77. Snider Jr. DE, Long MW, Cross FS, Farer LS (1984) Six-months isoniazidrifampin therapy for pulmonary tuberculosis. Am Rev Respir Dis 129: 573-579.
78. Long MW, Snider Jr. D, Farer LS (1979) U.S. public health service cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis. Am Rev Resp Dis 119: 879-894.
79. Tripathy SP (1979) Madras study of short-course chemotherapy in pulmonary tuberculosis. Bull Int Union Tuberc 54: 28-30. (Pubitemid 9234438)
80. Murray J, Sonnenberg P, Shearer S, Godfrey-Faussett P (2000) Drug-resistant pulmonary tuberculosis in a cohort of southern African goldminers with a high prevalence of HIV infection. S Afr Med J 90: 381-386. (Pubitemid 30303556)
81. East African British Medical Research Councils (1981) Controlled clinical trial of five short-course (4 month) chemotherapy regimens in pulmonary tuberculosis. Am Rev Respir Dis 123: 165-170.
82. Agounitestane D, Chiheb M, Khaled S, Khaled NA, Boulahbal F, et al. (1990) Essai thérapeutique d'une combinaison de trois médicaments essentiels dans la chimiothérapie courte de la tuberculose. Rev Mal Resp 7: 209-213. (Pubitemid 20237301)
83. Mazouni L, Tazir M, Boulahbal F, Chaulet P (1985) Enquête contrôlée comparant trois règimes de chiniothérapie quotidienne de six mois dans la tuberculose pulmonaire, en pratique de routine à Alger. Rev Mal Resp 2: 209-214. (Pubitemid 16198224)
84. East African and British Medical Research Councils (1978) Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. Lancet 2: 334.
85. El-Sadr WM, Perlman DC, Matts JP, Nelson ET, Cohn DL, et al. (1998) Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Clin Infect Dis 26: 1148-1158.
86. British Thoracic and Tuberculosis Association (1976) Short-course chemotherapy in pulmonary tuberculosis. Lancet ii: 1102.
87. Teo SK, Tan KK, Khoo TK (2002) Four-month chemotherapy in the treatment of smear-negative pulmonary tuberculosis: results at 30 to 60 months. Ann Acad Med Singapore 31: 175-181.
88. Chaulet P, Boulahbal F (1995) Essai clinique d'une combinaison en proportions fixes de trois medicaments dans le traitement de la tuberculose. Tuberc Lung Dis 76: 407-412.
89. Engbaek HC, Heckscher T, Hojgaard C, Larsen SO, Rasmussen KN, et al. (1981) Tuberculosis treated with rifampicin, ethambutol and isoniazid: Danish tuberculosis trial 1972-1974. Eur J Respir Dis 63: 84-93.
90. Sharifi-Mood B, Metanat M, Alavi-Naini R, Kouhpayeh HR, Salehi M, et al. (2006) The comparison of six-month and four-month regimens of chemotherapy in the treatment of smear positive pulmonary tuberculosis. J Med Sci 6: 108-111. (Pubitemid 43316309)
91. A Singapore-British Medical Research Council study (1978) Controlled trial of 4-month and 6-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Ann Acad Med 5: 242-243.
92. Maureen M, McGregor M, Olliaro P, Wolmarans L, Mabuza B, et al. (1996) Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. Am J Respir Crit Care Med 154: 1462-1467. (Pubitemid 26391198)
93. Hong Kong Chest Service, Tuberculosis Research Centre M, British Medical Research Council (1981) A controlled trial of 2-month, 3-month, and 12-month regimens of chemotherapy for sputum smear-negative pulmonary tuberculosis: the results at 30 months. Am Rev Respir Dis 124: 138-142. (Pubitemid 11044488)
94. Mohanty KC, Dhamgaye TM (1993) Controlled of ciprofloxacin in short-term chemotherapy for pulmonary tuberculosis. Chest 104: 1194-1198. (Pubitemid 23306077)
95. Kohno S, Koga H, Kaku M, Maesaki S, Hara K (1992) Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis. Chest 102: 1815-1818. (Pubitemid 23001233)
96. Mak A, Thomas A, Granado M, Zaleskis R, Mouzafarova N, et al. (2008) Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens. Am J Respir Crit Care Med 178: 306-312.
97. World Health Organization (2009) Treatment of tuberculosis: Guidelines. 4th Edition. Geneva: WHO. WHO/HTM/TB/2009.420.
98. Benator D, Bhattacharya M, Bozeman L, Burman W, Cantazaro A, et al. (2002) Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 360: 528-534.
99. Chang KC, Leung CC, Yew WW, Chan SL, Tam CM (2006) Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis. Am J Respir Crit Care Med 174: 1153-1158.
100. Li J, Munsiff SS, Driver CR, Sackoff J (2005) Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000. Clin Infect Dis 41: 83-91. (Pubitemid 40863749)
101. Caldwell DM, Ades AE, Higgins JPT (2005) Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 331: 897.
102. Song F, Loke YK, Walsh T, Glenny AM, Eastwood AJ, et al. (2009) Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. BMJ 338: b1147.
103. Greenaway C, Menzies D, Fanning A, Grewal R, Yuan L, et al. (2002) Delay in diagnosis among hospitalized patients with active tuberculosis - predictors and outcomes. Am J Respir Crit Care Med 165: 927-933. (Pubitemid 34774659)
104. Humphries MJ, Byfield SP, Darbyshire JH, Davies PDO, Nunn AJ, et al. (1984) Deaths occurring in newly notified patients with pulmonary tuberculosis in England and Wales. Br J Dis Chest 78: 149.
105. Allan WGL, Snell NJC, Hill LE, Fayers PM, Scadding JG, et al. (1981) A survey of deaths in Hong Kong attributed to tuberculosis. Tuberc 62: 1-11.
106. Davis MCE, McAllister K, Matthews CJ, Ognibene AJ (1985) Tuberculosis; cause of death in antibiotic era. Chest 88: 726.
107. Ramos JM, Padilla S, Masia M, Gutierrez F (2008) A bibliometric analysis of tuberculosis research indexed in PubMed, 1997-2006. In J Tuberc Lung Dis 12: 1461-1467.
108. Kieling C, Herrman H, Patel V, Mari JJ (2009) Indexation of psychiatric journals from low- and middle-income countries: a survey and a case study. World Psychiatry 8: 40-44.
109. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, et al. (2001) HIV- 1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 358: 1687-1693. (Pubitemid 33124328)
110. Hong Kong Chest Service, Tuberculosis Research Centre M-BMRC (1992) A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 145: 36-41.
111. East and Central African-British Medical Research Council Fifth Collaborative (1986) Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. Tuberc 67: 5-15. (Pubitemid 16160349)
112. Felten MK (1989) Importance of rifampicin in combined daily/intermittent chemotherapy for tuberculosis. S Afr Med J 75: 524-526.
113. East and Central African-British Medical Research Council Fifth Collaborative (1986) Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. Tuberc 67: 5-15. (Pubitemid 16160349)
114. East and Central African-British Medical Research Council Fifth Collaborative (1986) Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. Tuberc 67: 5-15. (Pubitemid 16160349)
115. Zierski M, Bek E, Long MW, Snider DE, Jr. (1981) Short-course (6-month) cooperative tuberculosis study in Poland: results 30 months after completion of treatment. Am Rev Respir Dis 124: 249-251.
116. Zierski M, Bek E, Long MW, Snider DE, Jr. (1980) Short-course (6 month) cooperative tuberculosis study in Poland: results 18 months after completion of treatment. Am Rev Respir Dis 122: 879-889.
117. Macnab MF, Bohmer PD, Seager JR (1994) Evaluation of the 3-drug combination, Rifater, versus 4-drug therapy in the ambulatory treatment of tuberculosis in Cape Town. S Afr Med J 84: 325-327.